Bristol Myers Squibb Company $BMY Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.3% during the second quarter, Holdings Channel reports. The firm owned 1,126,721 shares of the biopharmaceutical company’s stock after selling 26,606 shares during the quarter. HighTower Advisors LLC’s holdings in Bristol Myers Squibb were worth $64,922,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Life Cycle Investment Partners Ltd acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $34,406,000. Lazard Asset Management LLC lifted its position in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after acquiring an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC boosted its stake in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares during the period. Callan Family Office LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $3,575,000. Finally, BlackRock Inc. raised its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BMY. JPMorgan Chase & Co. raised their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Raymond James Financial started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Finally, TD Cowen initiated coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb currently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Stock Up 0.0%

Shares of Bristol Myers Squibb stock opened at $66.85 on Tuesday. The firm has a market cap of $136.56 billion, a price-to-earnings ratio of 14.72, a P/E/G ratio of 0.32 and a beta of 0.23. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The stock has a 50-day simple moving average of $63.09 and a 200-day simple moving average of $59.96.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.